Sun Pharma launches WINLEVI (clascoterone) cream 1% in US market

Used for topical treatment for acne vulgaris

Sun Pharmaceuticals Industries announced the availability of WINLEVI (clascoterone) cream 1% in the United States (U.S). A first-in-class topical androgen receptor inhibitor, WINLEVI was approved by the U.S. Food and Drug Administration (FDA) in August 2020 for the topical treatment of acne vulgaris in patients 12 years of age and older.

Powered by Capital Market - Live News